Introduction

Tacrolimus is a macrolide antibiotic isolated from Streptomyces tsukubanesis that has immunomodulatory properties; it is efficacious and widely used for the prevention of allograft rejection in patients undergoing liver transplantation (1). Although its action is similar to that of cyclosporin (CyA), the immunosuppressive effect is 10 to 20 times greater in vivo than that of CyA and its intestinal absorption is more reliable, even in the presence of gastrointestinal disease (2). Therefore, much attention has been directed to tacrolimus for patients with inflammatory bowel disease (IBD) that are refractory to conventional therapy. In several uncontrolled studies, tacrolimus improved fistulizing Crohn's disease (CD) and steroid-refractory ulcerative colitis (UC)
. A recent randomized control study demonstrated the efficacy and safety of oral tacrolimus for inducing remission of refractory UC (5 
Naganuma et al reported that G-CAP therapy is a promising option for patients with moderate UC that are refractory to conventional therapy, with regard to reducing and avoiding PSL readministration, but that five sessions of G-CAP is not very effective for patients with severe UC (6). In this case, we intensively performed G-CAP twice per week to reduce the colonic inflammation, because the patient did not respond to high-dose PSL administration. This combination therapy, however, was not effective for this patient. In addition, endoscopic findings revealed deep longitudinal ulcer, which was suggestive of impaired mucosal healing. We therefore started intravenous administration of tacrolimus, for expecting rapid onset of action and letting this patient go into remission as soon as possible, because azathioprine may be ineffective in this active phase for its delayed onset of action.
Generally, intravenous administration of CyA is effective as a rescue therapy for patients with severe UC. The rapid
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efficacy of CyA to avoid emergency colectomy is approximately 50% to 80% in UC, but 35% to 67% of patients eventually undergo surgery (7) (8) (9) (10) . In addition, maintenance of remission with CyA requires high doses that are frequently associated with significant side effects such as gingival hyperplasia, hypertrichosis, hypertension, diabetes, nephrotoxicity, and neurotoxicity (11) .
Another major disadvantage of CyA is the necessity to administer it intravenously to achieve sufficient, stable levels due to its variable intestinal absorption. The original oilbased oral formulation of CyA is characterized by high intra-and inter-patient's pharmacokinetic variability and poor bioavailability in patients with diarrhea, thereby preventing the stable blood levels of CyA (12) .
Tacrolimus, however, is well-absorbed orally, compared to intravenous administration, even in severe colitis (4, 13) . Moreover, recent evidence from transplant patients suggests that tacrolimus is superior to CyA with respect to immunosuppressive potency and has a lower incidence of side effects (14, 15) . Based on these findings, we selected tacrolimus for this patient.
Tacrolimus has immunosuppressive properties similar to CyA, but is approximately 100 times more potent than CyA (16) (3, 4, 18, 19 (19, 20) .
In 
